Contact this trialFirst, we need to learn more about you.
Tyrosine Kinase Inhibitor
Osimertinib + Bevacizumab for Lung Cancer
Recruiting2 awardsPhase 3
DeKalb, Illinois
This trial is testing whether adding bevacizumab to osimertinib will help patients with EGFR-mutated, stage IIIB-IV non-small cell lung cancer live longer, as compared to osimertinib alone.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.